Erschienen in:
04.07.2017 | Erratum
Erratum to: Insights on mid-term TAVR performance: 3-year clinical and echocardiographic results from the CoreValve ADVANCE study
verfasst von:
Sabine Bleiziffer, Johan Bosmans, Stephen Brecker, Ulrich Gerckens, Peter Wenaweser, Corrado Tamburino, Axel Linke, For the ADVANCE Study Investigators
Erschienen in:
Clinical Research in Cardiology
|
Ausgabe 10/2017
Einloggen, um Zugang zu erhalten
Excerpt
The sentence in the “Discussion” describing the new pacemaker rate was incorrect. The correct version of the sentence is: The new pacemaker rate at 3 years of 31.4% is slightly higher than the 28% reported in the CoreValve US Pivotal High Risk Trial [8], and considerably higher than that reported with balloon-expanding devices [9, 10]. …